It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study used a two-stage culture system to efficiently produce natural killer (NK) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in the absence of cell sorting and without need for xenogeneic stromal cells. Although different hESC and iPSC lines had varying efficiencies in hematopoietic development, all cell lines tested could produce functional NK cells. This improved method to develop NK cells from human pluripotent stem cells provides a system for clinical-scale expansion of antitumor lymphocytes and a genetically amenable platform to study human NK cell development.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Medicine (Hematology, Oncology, and Transplant); Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA
2 Division of Pediatrics, M.D. Anderson Cancer Center; School of Biomedical Sciences, Health Science Center, University of Texas, Houston, Texas, USA
3 Department of Medicine (Hematology, Oncology, and Transplant); Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA; International Clinical Research Center, Integrated Center of Cellular Therapy and Regenerative Medicine, St. Anne's University Hospital Brno, Brno, Czech Republic